Dataset opportunity
Insightmedbotics — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Insightmedbotics, usable for Diagnostic AI and Computer Vision.
Score
68.8
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market
Global AI in Medical Imaging market was valued at $1.8 billion in 2025, projected to grow at a CAGR of 35.1% (2026-2033) (source: Grand View Research). [1]
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-07-09
ForSight Robotics’ road to performing a fully robotic cataract surgery
therobotreport.com ↗ - 📰press2026-07-09
Stereotaxis closes Robocath takeover
medtechdive.com ↗ - 📰press2026-07-09
4 takeaways from MDUFA VI draft agreement
medtechdive.com ↗ - 📰press2026-07-09
J&J wins FDA approval for dual-energy ablation catheter
medtechdive.com ↗ - 📰press2026-07-09
Beyond da Vinci: Why versatile humanoid robots are the next frontier in surgery
therobotreport.com ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Real-time
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Mixed ownership — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Insightmedbotics holds a unique, multi-modal Medical Imaging Dataset that integrates a substantial image_collection with proprietary iot_data from its robotic systems and comprehensive longitudinal medical_records. This rich fusion of imaging, robotic telemetry, and clinical data provides an exceptional foundation for training and validating robust Diagnostic AI models with high contextual accuracy.
The business value of this asset is substantial, directly addressing the global AI in Medical Imaging market, which was valued at $1.8 billion in 2025 and is forecast to expand at a 35.1% CAGR. [1] While access is subject to strict privacy regulations and shared ownership agreements, the dataset's distinctive composition makes it a rare and highly valuable resource for buyers aiming to develop next-generation AI solutions in a rapidly growing market. ⚠ Diligence (valuable data, access to negotiate): Medical data subject to strict healthcare privacy regulations (HIPAA/PHIPA/GDPR); Clinical data ownership likely shared with research hospitals (Yale, Fox Chase); Proprietary robotic telemetry and spatial mapping data is highly specialized · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence collectively proves Insightmedbotics owns a proprietary dataset of high-resolution MRI images directly linked to robotic biopsy procedures for both prostate and breast cancer. This data is a rare and critical asset for medical-AI companies developing next-generation diagnostic AI for cancer detection and surgical guidance. In a market projected to grow at over 35% annually, this unique, FDA-cleared context data provides the ground truth needed to build and validate highly accurate, commercially viable models.
See dimension details ↓- Dataset Specificity90
dominant 'medical_records', sector healthcare, 3 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
real-time/streaming
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
Buyer demand for high-quality, multi-modal medical data is extremely high, driven by the explosive growth of the Diagnostic AI market, which has a projected CAGR of 35.1%. [1]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/regulated
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
high difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License28
ownership=mixed, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation56
2 data-appetite signals (2 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high, 5 recent external signals — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ good target — The company's core business is selling MRI-compatible robotic surgical systems, not data, and as a result, it is in a position to accumulate a highly valuable and unique dataset of procedural and imaging data as a by-product of its devices' use in clinical settings. [1, 15, 16] Issues: The company is a medical device vendor; the proprietary data would be generated by its customers (hospitals), which may introduce data ownership and access comp
- Deep Qualification90
⚠ needs review — Insight Medbotics is a medical device company, not a data seller; it develops and commercializes MRI-compatible robotic systems. The data generated is a by-product of its devices' clinical use, making the 'Medical Imaging Dataset' label coherent. Data ownership is complex and shared with clinical partners under strict medical regulations. [business model = tooling_vendor; licensing restricted]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
IoT / sensor data
This indicates the holder possesses precise spatial-temporal data from robotic procedures, which is invaluable for training AI in robotic navigation and automated surgical targeting.
Image collection
The holder owns a collection of high-resolution MRI images (up to 3T) from an FDA-cleared robotic platform, a premium asset for any company building regulated diagnostic AI tools.
Medical records / imaging
This points to a dataset from a clinical study on MRI-guided breast biopsy, offering gold-standard, outcome-linked data essential for proving model efficacy and safety.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
Coverage
Scanned sources
Deliverable
Premium dataset report
Insightmedbotics Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging market was valued at $1.8 billion in 2025, projected to grow at a CAGR of 35.1% (2026-2033) (source: Grand View Research). [1]. Investment score 68.8/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
Data Academy
Learn before you deal
- What is a Dataset Worth?3 min read
- How a Data Transaction Works3 min read
- What you are entitled to sell3 min read